ADRX ADARx Pharmaceuticals, Inc. - Common stock
NASDAQ close Oct 2, 2026ADRX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
ADRX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Not enough fundamentals data to compute this ratio group yet.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
Not enough fundamentals data to compute this ratio group yet.
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Activists & 5%+ owners 1 position
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| ORBIMED ADVISORS ISRAEL II LTD, ORBIMED ADVISORS LLC, ORBIMED CAPITAL GP VII LLC, ORBIMED ISRAEL GP II, L.P., OrbiMed Genesis GP LLC | Oct. 2, 2026 | 14.00% | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 9 insiders · 5 officers · 4 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Zhen Li | President and CEO | Sept. 24, 2026 A | · | 0 | 0 | $0 |
| Ryan Fisk | CFO and CBO | Sept. 24, 2026 A | · | 0 | 0 | $0 |
| Alan Robert Macleod | Chief Scientific Officer | Sept. 24, 2026 A | · | 0 | 0 | $0 |
| Rui (Nmn) Zhu | Chief Technology Officer | Sept. 24, 2026 A | · | 0 | 0 | $0 |
| Robert William Ackles | Chief People Officer | Sept. 24, 2026 A | · | 0 | 0 | $0 |
| CHIMOVITS EREZ | Director | Sept. 28, 2026 C | 9,292,025 | 1 | 0 | $1,045,772 |
| Simeon George | Director | Sept. 28, 2026 C | 592,593 | 3 | 0 | $27,200,000 |
| GORDON CARL L | Director | Sept. 28, 2026 C | 588,235 | 3 | 0 | $16,150,000 |
| SR One Capital Management, LLC | 10% owner | Sept. 28, 2026 C | 592,593 | 3 | 0 | $27,200,000 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.